Cartesian Therapeutics has announced updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate for generalised myasthenia gravis (MG), Descartes-08.

A coordinate system is a set of numbers that allows you to specify the location of a point in some space. The Cartesian coordinates is one such system, which uses a set of three numbers to specify ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash.

After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 ...

Scientists have known about the Cartesian Diver toy for hundreds of years. Raffaelo Maggiotti, a student of Galileo, first described it in writing in 1648. “Cartesian” is a term that may come from the ...

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC) announced the FDA has granted Regenerative Medicine Advanced Therapy designation for Descartes-08 for the treatment of myasthenia gravis.

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial.